Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1553 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Input Field |
Entered |
SERIAL NUMBER | 88155130 |
---|---|
LAW OFFICE ASSIGNED | LAW OFFICE 104 |
EXTENSION OF USE | NO |
MARK SECTION | |
MARK | mark |
LITERAL ELEMENT | UBRELVY |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
MARK STATEMENT | The mark consists of standard characters, without claim to any particular font style, size or color. |
OWNER SECTION (current) | |
NAME | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
MAILING ADDRESS | CLONSHAUGH BUSINESS and TECHNOLOGY PARK |
CITY | COOLOCK, DUBLIN |
ZIP/POSTAL CODE | D17E400 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Ireland |
PHONE | 714-246-5351 |
XXXX | |
OWNER SECTION (proposed) | |
NAME | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED |
MAILING ADDRESS | CLONSHAUGH BUSINESS and TECHNOLOGY PARK |
CITY | COOLOCK, DUBLIN |
ZIP/POSTAL CODE | D17E400 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Ireland |
PHONE | 714-246-5351 |
XXXX | |
CORRESPONDENCE INFORMATION (current) | |
NAME | Matthew O. Brady |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | Matthew.Brady@Allergan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | kent_alexander@Allergan.com |
CORRESPONDENCE INFORMATION (proposed) | |
NAME | Matthew O. Brady |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | Matthew.Brady@Allergan.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | kent_alexander@Allergan.com |
GOODS AND/OR SERVICES SECTION | |
INTERNATIONAL CLASS | 005 |
CURRENT IDENTIFICATION | Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body |
GOODS OR SERVICES | KEEP ALL LISTED |
FIRST USE ANYWHERE DATE | 01/22/2020 |
FIRST USE IN COMMERCE DATE | 01/22/2020 |
SPECIMEN FILE NAME(S) | \\TICRS\EXPORT18\IMAGEOUT 18\881\551\88155130\xml1 \ SOU0002.JPG |
\\TICRS\EXPORT18\IMAGEOUT 18\881\551\88155130\xml1 \ SOU0003.JPG | |
SPECIMEN DESCRIPTION | The specimens consist of jpgs of the inner and outer packaging for the pharmaceutical products UBRELVY. |
REQUEST TO DIVIDE | NO |
PAYMENT SECTION | |
NUMBER OF CLASSES IN USE | 1 |
SUBTOTAL AMOUNT [ALLEGATION OF USE FEE] | 100 |
TOTAL AMOUNT | 100 |
SIGNATURE SECTION | |
DECLARATION SIGNATURE | /mob/ |
SIGNATORY'S NAME | Matthew O. Brady |
SIGNATORY'S POSITION | Attorney of Record-Illinois Bar member |
DATE SIGNED | 04/08/2020 |
SIGNATORY'S PHONE NUMBER | 714-246-4788 |
FILING INFORMATION | |
SUBMIT DATE | Wed Apr 08 19:51:46 ET 2020 |
TEAS STAMP | USPTO/SOU-XXXX:XXXX:XXXX: XXX:XXXX:XXXX:XXXX:XXXX-2 0200408195146333952-88155 130-7104eebb7e7f8f2d5664f 795db7f3359d247cebc6c8c13 7bb67db0f3dcd48dd4a2-DA-5 1451027-20200408193734936 310 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1553 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
The signatory believes that the applicant is the owner of the mark sought to be registered. For a trademark or service mark application, the mark is in use in commerce on or in connection with all the goods/services in the application or notice of allowance, or as subsequently modified. For a collective trademark, collective service mark, collective membership mark application, the applicant is exercising legitimate control over the use of the mark in commerce by members on or in connection with all the goods/services/collective membership organization in the application or notice of allowance, or as subsequently modified. For a certification mark application, the applicant is exercising legitimate control over the use of the mark in commerce by authorized users on or in connection with the all goods/services in the application or notice of allowance, or as subsequently modified, and the applicant is not engaged in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant. |
|
The specimen(s) shows the mark as used on or in connection with the goods/services/collective membership organization in commerce. | |
To the best of the signatory's knowledge and belief, no other persons, except, if applicable, authorized users, members, and/or concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive. | |
To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support. | |
The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true. |